$47B in Revenue: Moderna Accused of Infringing on Technology to Develop COVID-19 Vaccine, Lawsuit Says
The complaint alleges that Moderna used the patented fluorescent protein technology without permission during preclinical through phase III trials and for marketing purposes, claiming the technology was critical for Moderna's vaccine development success, which has generated over $47 billion in revenues.

